Professor Jonathan Golledge is an NHMRC Practitioner Fellow and vascular surgeon recognised as an international leader in artery disease. During the last 15 years, he established a translational research program which has culminated in bringing multiple new drugs and management approaches to clinical trials. The largest of these, testing a repurposed drug for artery weakening, is just about to commence after being funded by the NHMRC and New Zealand Health Research Council for over $6 million. This trial will be the largest drug trial for artery weakening ever performed (5-fold bigger than any past trial) and involves sites in multiple countries.